山东省药用玻璃股份有限公司 投资者关系管理制度 第一章总则 一、为规范山东省药用玻璃股份有限公司（以下简称"公司"）投资者关系 管理工作，加强公司与投资者之间的信息沟通，完善公司治理结构，切实保护投 资者特别是中小投资者合法权益，根据《中华人民共和国公司法》、《中华人民共 和国证券法》、《上市公司投资者关系管理工作指引》、《上海证券交易所股票上市 规则》、《上海证券交易所上市公司自律监管指引第 1 号—规范运作》等有关法律 法规、规范性文件和《公司章程》的规定，结合公司实际情况，制订本制度。 二、投资者关系管理是指公司通过便利股东权利行使、信息披露、互动交流 和诉求处理等工作，加强与投资者及潜在投资者之间的沟通，增进投资者对公司 的了解和认同，以提升公司治理水平和企业整体价值，实现尊重投资者、回报投 资者、保护投资者目的的相关活动。 三、投资者关系管理的基本原则： 1、合规性原则。公司投资者关系管理应当在依法履行信息披露义务的基础 上开展，符合法律法规、规章及规范性文件、行业规范和自律规则、公司内部规 章制度，以及行业普遍遵守的道德规范和行为准则。 4、诚实守信原则。公司在投资者关系管理活动中应当注重诚信、坚 ...

山东省药用玻璃股份有限公司 会计师事务所选聘制度 第一章 总 则 第一条 为规范山东省药用玻璃股份有限公司（以下简称"公司"）选聘（含续聘、 改聘）会计师事务所的行为，切实维护股东利益，提高财务信息质量，保证财务 信息的真实性和连续性，支持会计师事务所依法公正执业，根据中国证监会的相 关规定，特制定本制度。 第二条 公司选聘执行会计报表审计业务的会计师事务所相关行为，应当遵照本 制度选聘程序，披露相关信息。选聘其他专项审计业务的会计师事务所，视重要 性程度可参照本制度执行。 第三条 公司选聘会计师事务所应当经董事会审计委员会审查，必须经董事会和 股东大会审议决定，董事会不得在股东大会决定前委任会计师事务所开展工作。 第四条 公司大股东、实际控制人不得在公司董事会、股东大会审议前，向公司 指定会计师事务所，不得干预公司董事会审计委员会独立履行审核职责。 第二章 会计师事务所执业质量要求 第五条 公司的会计师事务所应当符合证券法规定的资格，具有良好的执业质量 记录，并满足下列条件： （一）具有独立的法人资格； （二）具有固定的工作场所、健全的组织机构和完善的内部管理和控制制度； （三）熟悉国家有关财务会计方面的法 ...

证券代码：600529 证券简称：山东药玻 公告编号：2023-053 山东省药用玻璃股份有限公司 关于召开 2023 年第一次临时股东大会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、 召开会议的基本情况 召开的日期时间：2023 年 9 月 13 日 15 点 00 分 召开地点：山东省淄博市沂源县城药玻路 1 号山东药玻公司研发大楼辅楼会 议室 股东大会召开日期：2023年9月13日 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票 系统 (二) 股东大会召集人：董事会 (三) 投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结 合的方式 (四) 现场会议召开的日期、时间和地点 (五) 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自 2023 年 9 月 13 日 至 2023 年 9 月 13 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东大会召开当日的交易时间段，即 9:1 ...

中信证券股份有限公司关于山东省药用玻璃股份有限公司 使用银行承兑汇票、自有外币资金等支付募集资金投资 项目所需资金并以募集资金等额置换的核查意见 中信证券股份有限公司（以下简称"中信证券"或"保荐机构"）作为山东 省药用玻璃股份有限公司（以下简称"山东药玻"或"公司"）非公开发行股票 持续督导期间的保荐机构，根据《中华人民共和国公司法》《中华人民共和国证 券法》《证券发行上市保荐业务管理办法》《上海证券交易所股票上市规则》以及 《上海证券交易所上市公司自律监管指引第 11 号——持续督导》等有关法律、 法规和规范性文件的规定，对山东药玻使用银行承兑汇票、自有外币资金等支付 募集资金投资项目所需资金并以募集资金等额置换事项进行了审慎核查，发表核 查意见如下： 一、募集资金基本情况 经中国证券监督管理委员会《关于核准山东省药用玻璃股份有限公司非公开 发行股票的批复》（证监许可﹝2022﹞1852 号）核准，公司向特定对象非公开发 行人民币普通股（A 股）股票 68,646,366 股，每股发行价格为 27.19 元，共募集 资金人民币 1,866,494,691.54 元，扣除承销保荐费 24,024,843.7 ...

证券代码：600529 证券简称：山东药玻 编号：2023-050 山东省药用玻璃股份有限公司 第十届监事会第六次会议决议公告 本公司监事会及全体监事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 一、监事会会议召开情况 二、监事会会议审议情况 本次会议由监事会主席王发利先生主持，以记名投票方式审议通过了以下议 案： 1、审议通过了《公司2023年半年度报告全文及摘要》 监事会根据《证券法》等有关规定，对董事会编制的公司"2023年半年度报 告全文及摘要"进行了审核，并出具如下审核意见： （1）、公司《2023年半年度报告》的编制和审核程序符合法律、法规和《公 司章程》的各项规定； （2）、公司《2023年半年度报告》的内容与格式符合中国证监会和证券交 易所的各项规定，所包含的信息真实反映出公司报告期内的经营情况和财务状况 等事项； 具体内容详见同日在上海证券交易所网站上披露的《山东省药用玻璃股份有 限公司2023年半年度募集资金存放与使用情况的专项报告》。 山东省药用玻璃股份有限公司第十届监事会第六次会议通知于2023年8月15 日以书面方式 ...

Financial Performance - The company's operating revenue for Q1 2023 was ¥1,236,596,013.53, representing an increase of 18.66% compared to the same period last year[4] - Net profit attributable to shareholders was ¥166,520,090.53, reflecting an increase of 8.69% year-on-year[4] - The net profit for Q1 2023 was CNY 166,520,090.53, an increase of 8.6% compared to CNY 153,203,982.25 in Q1 2022[19] - Operating profit for Q1 2023 reached CNY 198,426,538.66, up from CNY 187,394,576.30 in the same period last year, reflecting a growth of 6.1%[19] - Total revenue from operating activities amounted to CNY 1,099,498,014.86, compared to CNY 821,270,785.11 in Q1 2022, indicating a significant increase of 34%[21] - Total revenue for Q1 2023 reached ¥1,236,596,013.53, an increase of 18.6% compared to ¥1,042,152,720.94 in Q1 2022[17] Cash Flow and Investments - The net cash flow from operating activities reached ¥210,561,918.95, showing a significant increase of 642.49% compared to the previous year[4] - Cash flow from operating activities showed a net inflow of CNY 210,561,918.95, a turnaround from a net outflow of CNY -38,813,883.36 in Q1 2022[21] - Investment activities generated a net cash outflow of CNY -164,943,991.10, compared to CNY -98,152,854.78 in the previous year, reflecting increased investment activities[22] - The company reported cash and cash equivalents at the end of Q1 2023 totaling CNY 1,203,910,256.34, up from CNY 569,953,519.22 at the end of Q1 2022[22] Assets and Liabilities - Total assets at the end of the reporting period were ¥8,930,331,690.45, up 1.66% from the end of the previous year[4] - Current assets totaled ¥5,447,562,092.77 as of March 31, 2023, compared to ¥5,320,914,051.87 at the end of 2022, marking an increase of 2.4%[13] - Non-current assets amounted to ¥3,482,769,597.68, up from ¥3,463,338,478.06, indicating a growth of 0.6%[14] - Total liabilities decreased to ¥1,802,253,625.27 from ¥1,822,573,049.80, a reduction of 1.1%[16] - Shareholders' equity increased to ¥7,128,078,065.18, up from ¥6,961,679,480.13, reflecting a growth of 2.4%[16] Earnings and Shareholder Information - Basic and diluted earnings per share were both ¥0.25, a decrease of 3.85% from the same period last year[4] - Basic and diluted earnings per share for Q1 2023 were both CNY 0.25, slightly down from CNY 0.26 in Q1 2022[20] - The number of ordinary shareholders at the end of the reporting period was 64,706, with the largest shareholder holding 19.50% of the shares[9] Other Income and Expenses - Non-operating income totaled ¥12,004,561.74 after tax impacts, with significant contributions from government subsidies and investment income[5] - Investment income increased by 1,130.98% due to higher returns from structured deposits[7] - The company recorded a significant increase in investment income, reaching CNY 6,515,358.27 compared to CNY 529,282.18 in the previous year[19] - Research and development expenses decreased to CNY 30,947,488.73 from CNY 33,596,760.33, a reduction of approximately 7.9%[19] Inventory and Current Assets - The company reported a decrease of 76.76% in other current assets due to a reduction in deductible VAT input tax[7] - Inventory decreased to ¥1,149,678,867.25 from ¥1,209,908,569.25, a decline of 4.9%[13] - Cash and cash equivalents rose to ¥1,378,886,187.30 from ¥1,352,049,912.52, an increase of 2.0%[13]

Financial Performance - The company's operating revenue for 2022 was CNY 4,187,279,279.75, representing an increase of 8.05% compared to CNY 3,875,304,663.58 in 2021[14] - The net profit attributable to shareholders for 2022 was CNY 618,287,086.47, which is a 4.60% increase from CNY 591,088,499.35 in the previous year[14] - The basic earnings per share for 2022 were CNY 1.03, up 4.04% from CNY 0.99 in 2021[15] - The weighted average return on equity for 2022 was 12.28%, a decrease of 1.01% from 13.29% in 2021[15] - The company reported a total of CNY 15,791,107.85 in non-recurring gains and losses for 2022, compared to CNY 18,847,007.13 in 2021[19] - The company achieved a significant increase in fair value financial assets, with a year-end balance of CNY 1,101,434,246.68, up from CNY 307,130,778.08 at the beginning of the year[20] - The company reported a slight decline in sales of its main products in 2022, but demand for borosilicate molded bottles remained strong, driven by ongoing consistency evaluations[21] - The company reported a gross profit margin of approximately 26.5% for 2022, compared to 25.5% in 2021[158] Cash Flow and Investments - The net cash flow from operating activities decreased by 66.36% to CNY 252,442,324.58, down from CNY 750,440,353.24 in 2021[14] - The net cash flow from investing activities decreased by 71.62% to approximately -¥1.49 billion, attributed to increased investment expenditures and reduced investment recoveries[51] - The net cash flow from financing activities increased significantly by 1,034.61% to approximately ¥1.67 billion, mainly due to funds raised from a private placement[51] - The company’s investment activities resulted in a net cash outflow of CNY -1,488,386,994.99, worsening from CNY -867,246,853.36 in the previous year[162] Assets and Liabilities - The total assets at the end of 2022 were CNY 8,784,252,529.93, a 37.05% increase from CNY 6,409,715,397.53 at the end of 2021[14] - The total liabilities were approximately CNY 1.82 billion, a rise of 4.8% compared to CNY 1.74 billion in the previous year[153] - The company's capital reserve increased to ¥2,687,350,859.49 from ¥913,676,914.83, indicating a growth of about 194.0%[156] - The total equity attributable to shareholders reached ¥6,512,947,412.26, compared to ¥4,321,061,577.10 in the previous year, marking an increase of about 50.7%[157] Research and Development - The total R&D investment for the period was CNY 138,937,775.86, accounting for 3.32% of total operating revenue[60] - The company developed 270 new products during the reporting period, confirming 112 samples, with a focus on high-value products such as vaccine stoppers[24] - The company has a strong R&D system, achieving significant advancements in lightweight and high-quality molded bottles, with several products already in mass production[47] Market and Competition - Major competitors in the pharmaceutical glass industry include Gerresheimer, Schott, and Zhengchuan Co., with a notable market share held by leading firms[32] - The pharmaceutical packaging materials industry in China has seen significant growth, with over 1,000 production enterprises, including more than 200 manufacturers of pharmaceutical glass, indicating a competitive landscape[31] - The company is actively exploring international markets through direct sales and partnerships, enhancing its global footprint in the pharmaceutical packaging sector[39] Quality Management and Compliance - The company has implemented a quality index to analyze various quality data quarterly, reflecting trends in product quality[25] - The pharmaceutical glass industry is regulated by the National Medical Products Administration, which oversees quality management and risk management for drug packaging materials[26] - The company has established a comprehensive packaging product system with over 1,000 specifications, catering to various customer needs in the pharmaceutical, healthcare, and cosmetics sectors[36] Environmental and Social Responsibility - The company invested 38 million RMB in environmental protection during the reporting period[103] - The company has upgraded its pollution control facilities to meet increasing environmental standards, collaborating with multiple environmental companies[106] - The company made a total social responsibility investment of 2.55 million yuan, including donations to educational and health initiatives[113] Governance and Management - The company’s governance structure is compliant with relevant laws and regulations, ensuring clear responsibilities among shareholders, the board, and management[72] - The total pre-tax remuneration for the board members and senior management during the reporting period amounted to CNY 1,626.1 million[77] - The company has established a remuneration decision-making process for directors and supervisors based on shareholder approval[80] Shareholder Structure and Equity - The total number of shares increased from 594,967,747 to 663,614,113 due to a non-public offering of shares, representing an increase of approximately 11.5%[128] - The largest shareholder, Shandong Luzhong Investment Co., Ltd., holds 19.50% of shares, totaling 129,380,980 shares, with 58,370,000 shares pledged[136] - The company’s private placement was approved for trading on May 24, 2023[133] Financial Reporting and Audit - The audit report confirms that the financial statements fairly represent the company's financial position as of December 31, 2022[143] - The company has implemented key internal controls related to revenue recognition to mitigate potential misstatement risks[146] - The company prepares its financial statements based on the going concern assumption and accrual basis of accounting[181]

证券代码：600529 证券简称：山东药玻 公告编号：2023-027 山东省药用玻璃股份有限公司 关于召开 2022 年度暨 2023 年第一季度业绩说明会的 公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 会议召开时间：2023 年 05 月 11 日(星期四) 上午 10:00-11:00 会议召开地点：上海证券交易所上证路演中心（网址： http://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2023 年 05 月 04 日(星期四) 至 05 月 10 日(星期 三)16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或 通过公司邮箱 sdyb@pharmglass.com 进行提问。公司将在说明会上对 投资者普遍关注的问题进行回答。 山东省药用玻璃股份有限公司（以下简称"公司"）已于 2023 年 4 月 25 日发布公司 2022 年度报告，为便于广大投资者更全面深入地 了解公司 2022 年度经营成果、财务状况，公司计划于 ...

Financial Performance - The company's operating revenue for Q3 2022 was ¥1,012,162,607.26, representing a year-on-year increase of 1.88%[4] - The net profit attributable to shareholders for Q3 2022 was ¥172,919,418.17, with a year-on-year increase of 2.51%[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥165,844,941.69, reflecting a year-on-year increase of 0.89%[4] - Total operating revenue for the first three quarters of 2022 reached ¥2,988,666,620.15, an increase of 6.5% compared to ¥2,805,526,162.50 in the same period of 2021[16] - Net profit for the third quarter of 2022 was ¥494,800,984.91, compared to ¥469,683,871.58 in the same quarter of 2021, representing a growth of 5.3%[17] - The company reported a total profit of ¥576,765,745.43 for the third quarter of 2022, up from ¥551,728,276.55 in the same quarter of 2021, reflecting a growth of 4.5%[17] Assets and Liabilities - The total assets at the end of the reporting period were ¥6,728,673,220.10, an increase of 4.98% compared to the end of the previous year[5] - The equity attributable to shareholders at the end of the reporting period was ¥4,994,661,126.66, up 6.95% from the previous year[5] - Total assets as of September 30, 2022, amounted to ¥6,728,673,220.10, an increase from ¥6,409,715,397.53 as of December 31, 2021[14] - Total liabilities amounted to ¥1,734,012,093.44, slightly down from ¥1,739,411,613.91 in the previous year[15] - The company’s total liabilities decreased to ¥1,673,286,549.71, down from ¥1,679,446,222.37, indicating a slight improvement in financial health[14] Cash Flow - The net cash flow from operating activities for the year-to-date was ¥199,142,085.64, showing a decline of 50.42% compared to the previous year[5] - In the first three quarters of 2022, the cash inflow from operating activities amounted to CNY 2,700,512,150.02, an increase of 11.7% compared to CNY 2,416,537,854.15 in the same period of 2021[19] - The net cash flow from operating activities for the first three quarters of 2022 was CNY 199,142,085.64, a decrease of 50.5% from CNY 401,691,941.00 in the previous year[21] - The cash outflow from operating activities totaled CNY 2,501,370,064.38, up 24.1% from CNY 2,014,845,913.15 in the same period of 2021[21] - The cash inflow from investment activities was CNY 658,903,823.63, compared to CNY 619,536,357.70 in the previous year, reflecting a growth of 6.3%[21] - The net cash flow from investment activities was -CNY 327,243,646.44, an improvement from -CNY 647,470,907.13 in the same period of 2021[21] Inventory and Receivables - The company's inventory increased by 36.63% year-to-date, primarily due to rising raw material costs and increased production capacity[7] - Accounts receivable increased to ¥842,522,069.40 from ¥764,358,649.73, reflecting a growth of about 10.2%[13] - Inventory rose significantly to ¥1,199,218,984.19, compared to ¥877,737,495.86, marking an increase of approximately 36.6%[13] Earnings and Expenses - The basic earnings per share for Q3 2022 was ¥0.2906, a year-on-year increase of 2.50%[5] - Earnings per share for the third quarter of 2022 were ¥0.8316, an increase from ¥0.7894 in the same quarter of 2021[18] - Research and development expenses for the third quarter of 2022 were ¥104,317,377.43, compared to ¥102,030,196.60 in the same quarter of 2021, showing an increase of 2.2%[17] Cash and Equivalents - Cash and cash equivalents decreased to ¥611,062,771.84 from ¥885,044,113.42 year-over-year, representing a decline of approximately 30.8%[13] - The cash and cash equivalents at the end of the period were CNY 426,933,280.24, down from CNY 607,130,365.18 at the end of the same period in 2021[21]

Financial Performance - The company's operating revenue for the first half of 2022 was CNY 1,976,504,012.89, representing a 9.07% increase compared to CNY 1,812,074,578.30 in the same period last year[12]. - The net profit attributable to shareholders of the listed company was CNY 321,881,566.74, up 6.94% from CNY 300,992,702.80 in the previous year[12]. - Basic earnings per share for the first half of 2022 were CNY 0.5410, a 6.94% increase from CNY 0.5059 in the same period last year[13]. - The total profit reached ¥385,747,053.16, up by ¥27,301,778.08 compared to the previous year, with a growth rate of 7.62%[32]. - The company reported a total cash balance of approximately RMB 786.80 million at the end of the period, down from RMB 885.04 million at the beginning of the period, indicating a decrease of about 11.1%[199]. Cash Flow and Investments - The net cash flow from operating activities decreased by 40.33%, amounting to CNY 112,706,438.89 compared to CNY 188,889,856.32 in the same period last year[12]. - Investment income fell by 36.96% to CNY 1.35 million, primarily due to a reduction in financial products[35]. - Cash inflow from investment activities was CNY 518,223,605.91, compared to CNY 414,851,812.69 in the previous year, representing an increase of approximately 25%[84]. - The net cash flow from investing activities was -¥207,352,152.85, an improvement from -¥420,724,101.38 in the first half of 2021[86]. Assets and Liabilities - The total assets at the end of the reporting period were CNY 6,681,114,607.10, an increase of 4.23% from CNY 6,409,715,397.53 at the end of the previous year[12]. - Total liabilities amounted to CNY 1,861,970,554.57, compared to CNY 1,739,411,613.91, representing an increase of about 7%[73]. - The company's intangible assets increased by 32.77% to CNY 263.37 million, attributed to new land acquisition and land use rights[37]. - The total amount of guarantees provided to subsidiaries during the reporting period was 4,344.65 million RMB, with a remaining balance of 3,041.26 million RMB[62]. Market Position and Strategy - The company is a leading player in the pharmaceutical glass industry, focusing on the production of various pharmaceutical glass bottles, including molded bottles, amber bottles, ampoules, and controlled bottles[18]. - The company actively explores international markets through a combination of direct sales and distribution channels[22]. - The domestic pharmaceutical manufacturing industry is experiencing favorable conditions, leading to rapid market demand growth and positively impacting the company's development[22]. - The company has established a comprehensive packaging product system with over a thousand specifications to meet diverse customer needs, demonstrating significant scale advantages in the industry[18]. Research and Development - The company has a well-established R&D system, actively engaging in technological innovation and product development[30]. - The company received 17 patent authorizations during the reporting period, including 1 invention patent[33]. - Research and development expenses for the first half of 2022 amounted to ¥69,759,134.86, slightly higher than ¥68,882,694.92 in the same period of 2021[78]. Environmental Compliance - The company has been listed as a key pollutant discharge unit by the Zibo Ecological Environment Bureau[47]. - Wastewater from production is fully recycled and not discharged externally[48]. - The company achieved stable and compliant emissions after upgrading its environmental protection facilities[50]. - The company has implemented a comprehensive environmental emergency response plan, filed with local authorities[51]. Shareholder Information - The total number of ordinary shareholders as of the end of the reporting period was 70,245[64]. - The largest shareholder, Shandong Luzhong Investment Co., Ltd., held 129,380,980 shares, accounting for 21.75% of the total shares, with 58,680,000 shares pledged[65]. - The company has not disclosed any significant related party transactions during the reporting period[59]. Operational Efficiency - The company employs a sales-driven production model, where production plans are based on sales forecasts or customer orders, ensuring efficient operations[23]. - The company has implemented strict quality control measures, achieving product quality that is close to international standards[28]. - The company has expanded its production bases in Baotou and Mianzu, significantly enhancing market reach and operational efficiency[27]. Financial Reporting and Compliance - The company’s financial statements comply with the requirements of the enterprise accounting standards[103]. - The company has maintained a consistent accounting policy with no significant changes reported during the period[92]. - The company applies the new leasing standard effective from January 1, 2021, recognizing right-of-use assets and lease liabilities at the commencement of the lease[175].